Xenikos

About:

Xenikos is developing a combination of two toxin-loaded anti-T-cell antibodies.

Website: http://www.xenikos.com/

Top Investors: RA Capital Management, European Innovation Council, OostNL, Medicxi, Sanquin

Description:

Xenikos aims to develop a new medicine, based on the action of antibodies that enables patients suffering serious immune diseases, or rejection after transplantation, to reset their immune system quickly and efficiently. Xenikos strives to develop new, innovative immunotherapy medicines to help restore patients’ health and save lives.